Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Schizophrenia bulletin

• Publication date

  2015-07-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1093/schbul/sbu151PMID 25368372PMCID PMC4466175
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Roles of Reward, Default, and Executive Control Networks in Set-Shifting Impairments in Schizophrenia

  2013cited by this paper
• Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia.

  2012cited by this paper
• Predictive Reward Signal of Dopamine Neurons

  2011cited by this paper
• Neural correlates of reward processing in schizophrenia--relationship to apathy and depression.

  2010cited by this paper
• Abnormal Responses to Monetary Outcomes in Cortex, but not in the Basal Ganglia, in Schizophrenia

  2010cited by this paper
• Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double‐blind randomized placebo‐controlled study

  2008cited by this paper
• Tolcapone Improves Cognition and Cortical Information Processing in Normal Human Subjects

  2007cited by this paper
• Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

  2007cited by this paper
• The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.

  2007cited by this paper
• Persistent negative symptoms in schizophrenia: an overview.

  2007cited by this paper
• Selective reinforcement learning deficits in schizophrenia support predictions from computational models of striatal-cortical dysfunction.

  2007cited by this paper
• Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up.

  2005cited by this paper
• Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy.

  2005cited by this paper
• Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia.

  2005cited by this paper
• Symptoms versus neurocognitive test performance as predictors of psychosocial status in schizophrenia: a 1- and 4-year prospective study.

  2005cited by this paper
• Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS.

  2004cited by this paper
• A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson’s disease

  2004cited by this paper
• Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline.

  2004cited by this paper
• Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia.

  2004cited by this paper
• Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction

  2004cited by this paper
• Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells.

  2002cited by this paper
• A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.

  2002cited by this paper
• Getting formal with dopamine and reward.

  2002cited by this paper
• Characterization of Extracellular Dopamine Clearance in the Medial Prefrontal Cortex: Role of Monoamine Uptake and Monoamine Oxidase Inhibition

  2001cited by this paper
• Molecular Basis of Neuroprotective Activities of Rasagiline and the Anti-Alzheimer Drug TV3326 [lpar;N-Propargyl-(3R) Aminoindan-5-YL)-Ethyl Methyl Carbamate]

  2001cited by this paper
• Rasagiline [N‐propargyl‐1R(+)‐aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

  2001cited by this paper
• Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity.

  1999cited by this paper
• Heroin addicts have higher discount rates for delayed rewards than non-drug-using controls.

  1999cited by this paper
• Deprenyl augmentation for treating negative symptoms of schizophrenia: a double-blind, controlled study.

  1999cited by this paper
• The effect of augmentation with moclobemide on symptoms of schizophrenia.

  1999cited by this paper
• Selegiline augmentation of antipsychotics for the treatment of negative symptoms in schizophrenia.

  1999cited by this paper
• Predictive reward signal of dopamine neurons.

  1998cited by this paper
• Temporal dynamics of brain activation during a working memory task

  1997cited by this paper
• Treatment of Negative Symptoms in Schizophrenia and Schizoaffective Disorder by Selegiline Augmentation of Antipsychotic Medication: A Pilot Study Examining the Role of Dopamine

  1996cited by this paper
• What are the functional consequences of neurocognitive deficits in schizophrenia?

  1996cited by this paper
• Working memory dysfunction in schizophrenia.

  1994cited by this paper
• L-deprenyl in treating negative symptoms of schizophrenia.

  1992cited by this paper
• A depression rating scale for schizophrenics.

  1990cited by this paper
• A Rating Scale for Drug-Induced Akathisia

  1989cited by this paper
• Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl.

  1987cited by this paper
• A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS

  1970cited by this paper
• The Brief Psychiatric Rating Scale

  1962cited by this paper

• Randomized double-blind inpatient study of a gluten-free diet for negative symptoms in people with schizophrenia.

  2026cites this paper
• Pharmacological Interventions for Negative Symptoms in Schizophrenia: A Systematic Review of Randomised Control Trials

  2025cites this paper
• Comprehensive evaluation of 45 augmentation drugs for schizophrenia: a network meta-analysis

  2024cites this paper
• Turning the Spotlight on Apathy: Identification and Treatment in Schizophrenia Spectrum Disorders

  2023cites this paper
• Monoamine Oxidase B (MAO-B): A Target for Rational Drug Development in Schizophrenia Using PET Imaging as an Example.

  2023cites this paper
• Precision-medicine findings from the FACE-SZ cohort to develop motivation-enhancing programs in real-world schizophrenia

  2022cites this paper
• Placebo Response in Trials of Negative Symptoms in Schizophrenia: A Critical Reassessment of the Evidence

  2022cites this paper
• The Associations between COMT and MAO-B Genetic Variants with Negative Symptoms in Patients with Schizophrenia

  2021cites this paper
• Review and meta-analysis of add-on tranylcypromine with antipsychotic drugs for the treatment of schizophrenia with predominant negative symptoms: a restoration of evidence

  2021cites this paper
• Role of Neurochemicals in Schizophrenia

  2020cites this paper
• Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis

  2019cites this paper
• The Role of Cannabis within an Emerging Perspective on Schizophrenia

  2018cites this paper
• Negative symptoms of schizophrenia: new developments and unanswered research questions.

  2018cites this paper
• Grey matter reduction in the caudate nucleus in patients with persistent negative symptoms: An ALE meta-analysis.

  2017cites this paper
• Managing Negative Symptoms of Schizophrenia: How Far Have We Come?

  2017cites this paper
• Treatment of negative symptoms: Where do we stand, and where do we go?

  2017cites this paper
• A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia

  2017cites this paper
• Association of the brain-derived neurotrophic factor Val66Met polymorphism with negative symptoms severity, but not cognitive function, in first-episode schizophrenia spectrum disorders

  2016cites this paper
• Drugs, games, and devices for enhancing cognition: implications for work and society

  2016cites this paper
• New Frontiers in Selective Human MAO-B Inhibitors.

  2015cites this paper